IceCure Medical Promotes Shay Levav To COO, As Company Expands Commercial Activities In U.S. Following FDA Marketing Clearance For ProSense

Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense®

CAESAREA, Israel, Nov. 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the promotion of Shay Levav to Chief Operating Officer, as the Company anticipates accelerating commercial momentum following ProSense®'s marketing authorization from the U.S. Food and Drug Administration ("FDA") for low risk breast cancer in October 2025. Mr. Levav will continue to lead the Company's Regulatory Affairs, Quality Assurance, and Clinical Affairs, under his new role, that he has overseen since 2020.